MetaVia (MTVA) shares were down 26% in recent Wednesday trading after the company reported positive results from its two-part phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis, or MASH.
Part 1 of the trial is evaluating DA-1241, which is a novel g-protein-coupled receptor 119 agonist, against a placebo, while part 2 is examining the efficacy of combining DA-1241 with sitagliptin, a DPP-4 inhibitor.
The trial showed that DA-1241 resulted in a statistically significant reduction in alanine transaminase levels at weeks four and eight, with a near-significant reduction observed at week 16, the company said, adding that statistically significant results were also observed in several secondary endpoints, including reductions in controlled attenuation parameter and hemoglobin A1C.
The drug also demonstrated a strong safety profile, with mostly mild adverse events and no drug-related serious adverse events. MetaVia said that out of 109 randomized patients, 95 successfully completed the dosing.
Price: 1.65, Change: -0.58, Percent Change: -26.01
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.